Transcatheter aortic valve replacement (TAVR) has become a standard treatment for severe symptomatic aortic stenosis (AS) in patients who are at intermediate-to-high risk for surgical valve replacement [1–5]. However, moderate or severe postprocedural paravalvular leakage (PVL) is considered a significant independent predictor of acute and long-term mortality [6–10].

The fully repositionable and retrievable transcatheter Lotus aortic valve has a unique adaptive seal designed to minimize PVL. The valve is deployed via controlled mechanical expansion, which allows for precise positioning. The safety and efficacy of the Lotus valve have been demonstrated in patients with severe AS at high or intermediate surgical risk in the Western world [11–15]. However, data about the use of the Lotus valve for Chinese patients are still lacking. Some studies reported that TAVR with the Lotus valve is feasible for bicuspid AS [16, 17]. Nevertheless, there are limited data comparing the Lotus valve in bicuspid and tricuspid AS.

Herein, we report on the 1-year clinical outcomes with the Lotus valve in the prospective LOTUS-CHINA study. This study was designed to assess the safety and efficacy of the Lotus valve system for patients with severe AS in a Chinese patient cohort (ClinicalTrials.gov registration number NCT02536703).

Methods

Study design and patient population

The LOTUS-CHINA trial is a prospective, open-label, single-arm study. Between November 2015 and January 2017, 23 patients diagnosed with severe AS were enrolled in this study. All patients were classified as New York Heart Association (NYHA) functional class ≥II, had symptoms attributable to severe AS such as angina pectoris or syncope and had transthoracic echocardiography (TTE) measurements consistent with severe AS (aortic valve area [AVA] < 1.0 cm², and a mean aortic pressure gradient [PGmean] > 40 mm Hg or a peak systolic velocity [Vmax] > 4 m/s). Patients were considered to be at high risk on the basis of a Society of Thoracic Surgery (STS) score of ≥8% [18] and if a multidisciplinary heart team—including an interventional cardiologist, a cardiothoracic surgeon, and an anesthetist—agreed that the subject was likely to benefit from TAVR, was frail and/or had comorbidities associated with high surgical risk.

Data collection was followed by a study protocol that was approved by the local ethics committee, and registered with ClinicalTrials.gov (NCT02536703). All enrolled patients gave written informed consent.

Patient characteristics including age, gender, clinical symptoms, STS score, comorbidities etc. were collected. Baseline TTE measurements were collected including AS severity (AVA, PGmean, and Vmax), left ventricular function, and pulmonary pressure. Patient inclusion and exclusion criteria were followed as per the published protocol on ClinicalTrials.gov (NCT02536703). Procedural results as well as 30-day and 1-year outcomes were measured according to the Valve Academic Research Consortium (VARC)-2 criteria [19].

The primary endpoints were all-cause mortality, myocardial infarction, and stroke at 30 days after the procedure. Procedural complications, functional status (NYHA classification), and echocardiographic prosthesis status at 30 days and 1 year were reported as the secondary endpoints. Additionally, the study also compared procedural characteristics and...
Table 1  Baseline characteristics of patients with TAV and BAV

| Clinical characteristics | TAV (N = 14) | BAV (N = 9) | p  |
|--------------------------|-------------|-------------|----|
| Age (years)              | 76.9±5.7    | 71.2±4.8    | 0.02 |
| Female, n (%)            | 5 (35.7)    | 6 (66.7)    | 0.15 |
| STS score (%)            | 9.8±7.8     | 5.5±3.0     | 0.13 |
| NYHA class III or IV, n (%) | 11 (78.6) | 8 (88.9)    | 0.52 |
| Diabetes mellitus, medically treated, n (%) | 1 (7.14) | 2 (22.2)   | 0.30 |
| History of PCI or CABG, n (%) | 0 (0)    | 2 (22.2)    | 0.07 |
| History of atrial fibrillation, n (%) | 3 (21.4) | 1 (11.1)    | 0.52 |
| History of peripheral vascular disease, n (%) | 3 (21.4) | 1(11.1)     | 0.52 |
| History of cerebrovascular accident, n (%) | 3 (21.4) | 1 (11.1)    | 0.52 |
| COPD, n (%)              | 1 (7.14)    | 3 (33.3)    | 0.11 |
| Chronic renal failure, n (%) | 3 (21.4) | 2 (22.2)    | 0.96 |
| Echocardiographic assessment |             |             |    |
| Aortic valve area (effective orifice area; cm²) | 0.63±0.19 | 0.60±0.15  | 0.67 |
| Mean aortic valve gradient (mm Hg) | 50.8±8.9  | 52.6±9.0   | 0.65 |
| Peak velocity (m/s)      | 4.6±0.6     | 4.7±0.5     | 0.65 |
| Left ventricular ejection fraction (%) | 52.9±11.5 | 54.0±15.5  | 0.85 |
| Aortic regurgitation (moderate or severe), n (%) | 8 (57.1)  | 0 (0)       | 0.005 |
| Computed tomography assessment |            |             |    |
| Area-derived diameter (mm) | 24.0±1.8  | 24.4±2.5    | 0.64 |
| Perimeter-derived diameter (mm) | 24.5±1.8  | 24.9±2.7   | 0.70 |
| Severe aortic cusp calcification, n (%) | 1 (7.1)    | 3 (33.3)    | 0.11 |

Values are mean± standard deviation or number (%)  
BAV bicuspid aortic valve, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, NYHA New York Heart Association, PCI percutaneous coronary intervention, STS Society of Thoracic Surgeons, TAV tricuspid aortic valve

postprocedural outcomes between tricuspid aortic valves (TAVs) and bicuspid aortic valves (BAVs).

Device characteristics

The Lotus valve system (Boston Scientific Corporation, Natick, MA, USA) consists of a bioprosthetic aortic valve (a braided nitinol wire frame with three bovine pericardial leaflets) premounted on a preshaped delivery catheter. The valve is deployed via controlled mechanical expansion, which enables predictable and precise placement. The lower half of the Lotus valve is surrounded by a polymer membrane designed to fill the space between the native annulus and the prosthetic valve frame, thereby reducing PVL. The Lotus valve begins functioning early in the deployment process, providing hemodynamic stability and negating the need for rapid pacing.

Valvular function can be assessed in the fully expanded position prior to release. Partial or full recapturing/repositioning of the valve, or full retrieval, is possible at any point before uncoupling and release.

Computed tomography assessment and implantation procedure

Computed tomography angiography (CTA) was performed on all patients before the procedure using a second generation dual-source CT (SOMATOM Definition Flash, Siemens Medical Solutions, Forchheim, Germany). All CT images were measured by a Core Imaging Lab (Corelab) based in central Europe utilizing standardized software (3mensio Medical Imaging; Pie Medical Imaging, Maastricht, The Netherlands). To evaluate the aortic valvular structures, end-systolic images were used.

The final valve size for implantation was determined both by Corelab-based measurements in relation to a company-recommended sizing chart as well as operator experience. Valve oversizing in relation to the annulus was calculated as follows: (actual Lotus valve area/annular area measured by CT-1) × 100%.

All procedures were performed in a hybrid catheterization laboratory via the transfemoral approach. The procedure was performed on 20 patients (87%) with local anesthesia and on three (13%) patients with general anesthesia. A transesophageal echocardiographic (TEE) probe was placed and a temporary pacing wire was inserted into the right ventricle prior to valve implantation. The femoral access was pre-closed with two ProGlide devices (Abbott Vascular, Santa Clara, CA, USA). A preshaped TAVR 0.035-inch guidewire (Safari wire, Boston Scientific, Marlborough, MA, USA) was selected to avoid the complication of left ventricular perforation and to allow for stable advancement of the delivery system. Balloon valvuloplasty was performed according to the operator’s discretion.

The Lotus valve was implanted without rapid pacing. The valve position and PVL were assessed by TEE and aortography [20]. Three valve sizes (23 mm, 25 mm, and 27 mm) were used in this study cohort. The valve was implanted via an 18-F (23- and 25-mm device sizes) or 20-F (27-mm device) proprietary introducer sheath.

Statistical analysis

All statistical analyses were undertaken with SPSS software (version 20; IBM Corporation, Somer, NY, USA). Continuous variables are described as mean± standard deviation and compared with a paired Student t test. Categorical variables are expressed as counts and percentages and compared with a chi-square test. The first 12 Lotus TAVR procedures were categorized as early experience. A separate analysis was performed between early (N=12) and late experience (N=11) outcome data. A p value<0.05 was considered statistically significant.
Between November 2015 and January 2017, 23 patients underwent successful Lotus valve implantation. The mean age was 74.7±5.9 years, 47.8% were female, and the mean STS score was 8.1±6.8. No patients were lost to follow-up or death. The mean patient follow-up was 74.7±5.9 years, 47.8% were female, and the mean STS score was 8.1±6.8. No patients were lost to follow-up or death.

Results

Patient characteristics

In 23 patients, the aortic valve replacement was successful for all patients. Balloon valvuloplasty was performed on 19 patients, and four received a postprocedural pacemaker. There were no deaths, strokes, or major adverse cardiac and cerebrovascular events in 22 of the 23 patients. In the remaining patient, a full retrieval of the valve was successful, and the valve area increased from 0.6 to 0.2 cm² and the valve leakage was absent or mild. Nine patients (39%) had bicuspid valve stenosis, and three patients had large annulus valves. Three patients had small annulus valves. One patient had a large annulus valve with significant AR in the TAV group (p<0.001) at 30 days. Paravalvular leakage was absent or mild, and no patient had severe paravalvular leakage.

Device performance and procedural results

In 23 patients, the aortic valve replacement was successful for all patients. Balloon valvuloplasty was performed on 19 patients, and four received a postprocedural pacemaker. There were no deaths, strokes, or major adverse cardiac and cerebrovascular events in 22 of the 23 patients. In the remaining patient, a full retrieval of the valve was successful, and the valve area increased from 0.6 to 0.2 cm² and the valve leakage was absent or mild. Nine patients (39%) had bicuspid valve stenosis, and three patients had large annulus valves. Three patients had small annulus valves. One patient had a large annulus valve with significant AR in the TAV group (p<0.001) at 30 days. Paravalvular leakage was absent or mild, and no patient had severe paravalvular leakage.
Hemodynamic and patient clinical outcomes

Patients exhibited significantly improved valve hemodynamics from baseline to discharge, at 30 days and at 1 year (Fig. 1a–d). PGmean decreased from 51.5 ± 8.8 mm Hg at baseline to 14.5 ± 3.6 mm Hg (p < 0.001), Vmax decreased from 4.61 ± 0.53 m/s to 2.61 ± 0.32 m/s (p < 0.001), and AVA increased from 0.62 ± 0.17 cm² to 1.57 ± 0.15 cm² (p < 0.001) at 30 days. These effects were maintained at 1 year, with a PGmean value of 13.4 ± 4.9 mm Hg (p < 0.001 vs. baseline), a Vmax value of 2.48 ± 0.46 m/s (p < 0.001 vs. baseline), and an AVA value of 1.51 ± 0.40 cm² (p < 0.001 vs. baseline). There was no difference in hemodynamic improvement between BAV and TAV patients. No moderate or severe PVL was observed, whereas mild PVL occurred in eight patients (34.8%), three of which had BAVs. The VARC-2 defined clinical outcomes at 30 days and 1 year are shown in Table 3. There were no MACCE events, life-threatening/disabling bleeding, or major vascular complications at the 30-day postimplantation follow-up, and the all-cause mortality rate at 1 year was 4.5% (one out of 23). NYHA functional class was improved by at least two levels in eight patients (34.8%) at 30 days (p < 0.001 vs. baseline). The improvement was maintained for at least 1 year (Fig. 1e). There was no significant difference in procedural and 30-day or 1-year outcomes between the TAV and BAV groups (Table 4).

One patient had 70% right femoral stenosis after removal of the delivery sheath; a stent was implanted accordingly without any resultant limb ischemia. Three patients (13%) had BARC (Bleeding Academic Research Consortium)-defined major bleeding, in whom no cause other than procedural-related blood loss was identified. One patient developed VARC stage 3 acute
renal impairment with resolution of the creatinine to baseline on day 4.

Six patients (26.1%) required new permanent pacemaker implantation (PPI) owing to complete (third degree) atrioventricular block or complete left bundle branch block (LBBB) with symptomatic bradycardia. It is noteworthy that these six cases involved TAVs whereas no patient in the BAV group needed new PPI (50% vs. 0%, \( p = 0.006\)). Deeper implantation below the left coronary sinus (LCS) and greater degree of annulus oversizing were each independently associated with the occurrence of new-onset LBBB and the requirement for a new PPI. Postprocedural CT assessment revealed that the implantation depth at the LCS in patients who needed a pacemaker was significantly greater than those who did not need a pacemaker (5.75 ± 1.88 mm vs. 3.19 ± 2.24 mm, \( p = 0.02\)), and the difference in implantation depth also existed between TAVs and BAVs (4.88 ± 1.88 mm vs. 2.75 ± 2.47 mm, \( p = 0.03\)). The implantation depth in the noncoronary sinus (NCS), however, did not differ significantly between the two groups.

Three patients were declined assessment by Corelab because the annular dimensions were beyond the manufacturer recommended sizing range for the Lotus valve; two of these patients had BAVs with moderate-to-severe calcification at the annular and leaflet levels, while the other had a TAV with mild calcification continuous between the fused left and right coronary leaflets. Owing to the high surgical risk and the patients’ refusal of surgical valve replacement, it was decided to proceed with TAVR using the Lotus pros thesis following a multidisciplinary heart team assessment of CT dimensions. A 25-mm Lotus valve was implanted in one patient who had severe calcifications in the left coronary sinus; 27-mm Lotus valves were implanted in the other two patients, which equated to undersizing in relation to the annulus of –5.4%, –18.6%, and –14.1%, respectively, significantly lower than manufacturer sizing recommendation. These downsized Lotus valves were successfully deployed in the proper anatomical position with an obvious waist on the prosthesis at the annular level. Device implantation was successful in all three patients, without any complications according to the VARC-2 (Table 5).

**Discussion**

This is the first Chinese study to evaluate the acute and 1-year safety, efficacy, and clinical outcomes of the Lotus TAVR system in symptomatic high-risk surgical patients with severe aortic valve stenosis, while also comparing BAV and TAV patient subgroups. There were no deaths or strokes within 30 days, no residual moderate or severe PVL, and no significant differences in clinical outcomes between BAV and TAV patients.

The reported prevalence of BAV deformities is 0.5%–2% [21]. Patients presenting for TAVR in the Chinese population have a very high frequency of BAV morphology, close to 50%, which far exceeds

---

**Table 2** Procedural characteristics and outcomes

| Characteristics | TAV (N = 14) | BAV (N = 9) | \( p \) |
|----------------|-------------|------------|------|
| General anesthesia | 3 (21.4) | 0 (0) | 0.14 |
| Transfemoral | 14 (100) | 9 (100) | – |
| Predilatation | 13 (92.9) | 6 (33.3) | 0.11 |
| Postdilatation | 1 (7.1) | 0 (0) | 0.41 |

**Procedural outcomes (N = 23)**

| Absence of procedural mortality | 14 (100) | 9 (100) | – |
| Successful access, delivery, deployment, delivery system retrieval | 13 (92.9) | 9 (100) | 0.41 |
| Successful partial valve resheathing, if attempted (N = 10) | 8 (57.1) | 2 (22.2) | 0.10 |
| Successful valve retrieval, if attempted (N = 1) | 1 (7.1) | 0 | 0.41 |
| TAV-in-TAV deployment | 0 | 1 (11.1) | 0.20 |
| Correct positioning of a single valve into proper location | 13 (92.9) | 9 (100) | 0.41 |
| Indexed EOA > 0.85 cm²/m² | 11 (78.6) | 7 (77.8) | 0.96 |
| PGmean < 20 mm Hg or Vmax < 3 m/s | 11 (78.6) | 8 (88.9) | 0.52 |
| No moderate/severe PVL | 14 (100) | 9 (100) | – |

**Table 3** Clinical outcomes at 30 days and 1 year

| Outcomes (N = 23) | 30 days | 1 year |
|------------------|--------|-------|
| All-cause mortality | 0 (0.0) | 1 (4.5) |
| All stroke | 0 (0.0) | 0 (0.0) |
| Urgent/emergent conversion to surgery or repeat procedure for valve-related dysfunction | 0 (0.0) | 0 (0.0) |
| Minor vascular complications | 1 (4.3) | 1 (4.3) |
| Major bleeding | 3 (13.0) | 3 (13.0) |
| Acute kidney injury of stage 1 | 1 (4.3) | 1 (4.3) |
| Periprocedural coronary obstruction (≤ 72 h) | 0 (0.0) | 0 (0.0) |
| Myocardial infarction | 0 (0.0) | 0 (0.0) |
| Conduction disturbance requiring new pacemaker | 6 (26.1) | 6 (26.1) |

**Values are number (%)**

BAV bicuspid aortic valve, EOA effective orifice area, PGmean mean aortic valve gradient, PVL paravalvular leakage, TAV tricuspid aortic valve, Vmax peak velocity

*All were BMI < 30 kg/m²*
the frequency in the Western world, and with an enormous calcium burden, which presents challenges for TAVR in this population [22]. TAVR for bicuspid AS was regarded as a relative contraindication in early guidelines owing to the unfavorable anatomical characteristics, such as annular eccentricity, asymmetric leaflet calcifications, and dilated ascending aorta, which led to a higher risk of paravalvular regurgitation, annulus rupture, aortic dissection, or other poorer outcomes after the procedure [23–29]. The Lotus valve is designed to minimize PVL with its unique Adaptive Seal technology. In addition, the ability to recapture and reposition allows the operator to fully assess valve performance and the degree of PVL in its fully expanded form before release. The clinical outcomes of TAVR with the Lotus valve in patients with bicuspid AS are suggested to be superior to those following implantation of early-generation devices [16, 30, 31]. In the current study, the nine patients with bicuspid AS showed similar procedural outcomes to the 14 patients with tricuspid AS. This finding confirms that the Lotus valve is safe and efficient for the treatment of bicuspid AS. Trials utilizing the Lotus aortic valve replacement system have consistently shown an incidence of new PPI that is higher when compared with balloon-expandable valves, although similar to that following implantation of self-expanding valves [32–39]. The reported new PPI rate of 26.1% in this study is comparable to that reported previously (REPRISE I: 36%; REPRISE II: 28.6%; RESPOND: 30.0%; RELEVANT: 30.7%; [40–43]). The pacing rate reduced significantly as operator experience increased. After realizing that the conduction disturbance that may result in new PPI was associated with valve implantation depth and the degree of annulus oversizing during the learning curve, we modified our valve sizing protocol and minimized the implantation depth for late-experience patients. The lower incidence of new-onset LBBB and new PPI partly confirmed the relevance of these findings.

Table 4 Clinical outcomes of patients with TAV and BAV

| Outcomes at 30 days | TAV (N = 14) | BAV (N = 9) | p |
|---------------------|-------------|-------------|---|
| All-cause mortality, n (%) | 0 (0.0) | 0 (0.0) | – |
| All stroke, n (%) | 0 (0.0) | 0 (0.0) | – |
| Indexed EOA > 0.85 cm²/m², n (%) | 11 (78.6) | 7 (77.8) | 0.96 |
| Mean aortic valve gradient < 20 mm Hg or peak velocity < 3 m/s, n (%) | 11 (78.6) | 8 (88.9) | 0.52 |
| No moderate/severe PVL | 0 (0.0) | 0 (0.0) | – |
| NYHA class III or IV, n (%) | 3 (21.4) | 1 (11.1) | 0.52 |
| Conduction disturbance requiring new pacemaker, n (%) | 3 (21.4) | 3 (33.3) | 0.53 |

Outcomes at 1 year

| All-cause mortality, n (%) | 1 (7.1) | 0 (0.0) | 0.33 |
| All stroke, n (%) | 0 (0.0) | 0 (0.0) | – |
| Indexed EOA > 0.85 cm²/m², n (%) | 11 (78.6) | 7 (77.8) | 0.96 |
| Mean aortic valve gradient < 20 mm Hg or peak velocity < 3 m/s, n (%) | 11 (78.6) | 8 (88.9) | 0.52 |
| No moderate/severe PVL | 0 (0.0) | 0 (0.0) | – |
| NYHA class III or IV, n (%) | 3 (21.4) | 1 (11.1) | 0.52 |
| Conduction disturbance requiring new pacemaker, n (%) | 3 (21.4) | 3 (33.3) | 0.53 |

Table 5 Patients declined by Corelab owing to large annulus size

| Valve type | AreaD (mm²) | PeriD (mm) | Calcification | AreaD (mm²) | PeriD (mm) | Lotus valve size | Echocardiographic assessments post TAVR |
|------------|-------------|------------|---------------|-------------|------------|----------------|----------------------------------------|
| Bicuspid (type 1) | 27.8 | 28.8 | Moderate to severe | 29.5 | 30.8 | 27 | no | 1.55 | 11 | 2.3 | no |
| Bicuspid (type 0) | 27.7 | 28.1 | Moderate to severe | 29.5 | 30.3 | 25 | no | 1.74 | 10 | 2.2 | no |
| Tricuspid (functional bicuspid) | 29.1 | 29.4 | Moderate | 29.3 | 29.6 | 27 | no | 1.53 | 15 | 2.7 | no |

AR: aortic regurgitation, AreaD: area-derived diameter, AVA: aortic valve area, LVOT: left ventricular outlet tract, PeriD: perimeter-derived diameter, PVL: paravalvular leakage, PGmean: mean aortic valve gradient, PPI: permanent pacemaker implantation, PVL: paravalvular leakage, TAVR: transcatheter aortic valve replacement

Values are mean ± SD deviation or number (%)

BAV: bicuspid aortic valve, MACCE: major adverse cardiovascular or cerebrovascular events, NYHA: New York Heart Association, PVL: paravalvular leakage, STS: Society of Thoracic Surgeons, TAV: tricuspid aortic valve
A large-scale study is warranted for further confirmation.

According to the recommendations in the Boston Scientific Lotus sizing charts, patients with an annulus size of >27 mm are not considered to meet the minimal anatomical requirements as per the patient evaluation criteria, and would be declined a Lotus valve. In our experience, this is not necessarily the case. By undersizing of the valve, this group of patients may still benefit from TAVR using the Lotus device, suggesting that additional evaluation criteria beyond annular diameters and calcification scores need to be combined in the decision-making.

Study limitations

The fact that a small number of patients were enrolled, a randomized control group was absent, and the follow-up duration was short are limitations of this study. Moreover, there was no independent Corelab to analyze the echocardiographic data and to control the quality of the clinical data collection and accuracy.

Conclusion

Our single-center experience showed that the Lotus valve is feasible and effective for Chinese patients with aortic valve stenosis and atypical anatomy, including BAVs and a large aortic annulus. However, a large-scale study is still warranted in the Chinese population to fully evaluate the efficacy and safety of the Lotus valve system.

Corresponding address

J. Wang
Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine
310009 Hangzhou, China
wangjianan111@zju.edu.cn

Acknowledgements. This work was supported by the Advanced Technique Research of Valvular Heart Disease Treatment Project (2015C03028). The authors thank Cody R. Hou for his assistance in the manuscript preparation.

Compliance with ethical guidelines

Conflict of interest. Q. Xu, X. Liu, J. Jiang, Y. He, Q. Zhu, F. Gao, F. Wu, W. He, J. Cheng, M. Kong, Z. Pu, Q. Zhou, R. Gooley, and J. Wang declare that they have no competing interests.

The study protocol was approved by the local ethics committee and registered with ClinicalTrials.gov (NCT02536703). Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Nishimura RA, Otto CM, Bonow RO et al (2017) 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on Clinical Practice Guidelines. J Am Coll Cardiol 70(2):252–289
2. Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374(17):1609–1620
3. Adams DH, Popma JJ, Reardon MJ et al (2014) Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370(19):1790–1798
4. Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363(17):1597–1607
5. Thyregod HG, Steinbruchel DA, Ihlemann N et al (2015) Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 65(20):2184–2194
6. Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299–308
7. Abdel-Wahab M, Zahn R, Horack M et al (2011) Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart 97:899–906
8. Kodali SK, Williams MR, Smith CR et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366:1686–1695
9. Athappan G, Patvardhan E, Tuzcu EM et al (2013) Incidence, predictors and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol 61:1585–1595
10. Sinning JM, Vasa-Nicotera M, Chin D et al (2013) Evaluation and management of paravalvular aortic regurgitation following transcatheter aortic valve replacement. J Am Coll Cardiol 62:11–20
11. Meredith IT, Worthy SG, Whitbourn RJ et al (2014) Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRIZE study. EuroIntervention 9:1264–1270
12. Meredith IT, Walters DL, Dumontel N et al (2014) Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system, 30-day primary endpoint results from the REPRIZE I study. J Am Coll Cardiol 64:1339–1349
13. Wöhrle J, Gonska B, Rodewald C et al (2016) Transfemoral aortic valve implantation with the repositionable Lotus Valve for treatment of patients with symptomatic severe aortic stenosis: results from a single-centre experience. EuroIntervention 12:760–767
14. Backer OD, Gotberg M, Hiberg L et al (2016) Efficacy and safety of the Lotus Valve System for treatment of patients with severe aortic valve stenosis and intermediate surgical risk: results from the Nordic Lotus-TAVR Register. Int J Cardiol 219:92–97
15. Montone RA, Testa L, Fraccaro C et al (2017) Procedural and 30-day clinical outcomes following transcatheter aortic valve replacement with lotus valve: results of the RELEVANT study. Catheter Cardiovasc Interv 90(7):1206–1211
16. Yoon SH, Lefèvre T, Ahn JM et al (2016) Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol 68(11):1195–1205
17. Presbitero P, Iannetta L, Pagnotta P et al (2018) Transcatheter aortic valve implantation in bicuspid anomaly: procedural results with two different types of valves. Minerva Cardioangiol 66(2):129–135
18. O’Brien SM, Shahian DM, Filardo G et al (2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2-isolated valve surgery. Ann Thorac Surg 88(1 Suppl):S23–S42
19. Kappetein AP, Head SJ, Généreux P et al (2013) Updated standardized endpoint definitions for transcatheter aortic valve implantation, the valve academic research consortium-2 consensus document. J Thorac Cardiovasc Surg 145(1):6–23
20. Wöhrle J, Gonska B, Rodewald C et al (2015) Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve. Int J Cardio 195:171–175
21. Siu SC, Silversides CK (2010) Bicuspid aortic valve disease. J Am Coll Cardiol 55(25):2789–2800
22. Jilaihawi H, Wu Y, Yang Y et al (2015) Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv 85(Suppl 1):S52–S71
23. Wijesinghe N, Ye J, Rodés-Cabau J et al (2010) Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis. JACC Cardiovasc Interv 3:1122–1125
24. Himbert D, Pontnau F, Messika-Zeitoun D et al (2012) Feasibility and outcomes of transcatheter aortic valve implantation in high-risk patients with stenotic bicuspid aortic valves. Am J Cardiol 110:877–883
25. Bauer T, Linke A, Sievert H et al (2013) Comparison of the effectiveness of transcatheter aortic valve implantation in patients with stenotic bicuspid versus tricuspid aortic valves (from the German TAVI Registry). J Am Coll Cardiol 113:518–521
26. Hayashida K, Bouvier E, Lefèvre T et al (2013) Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. Circ Cardiovasc Interv 6:284–291

27. Mylotte D, Lefèvre T, Søndergaard L et al (2014) Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol 64:2330–2339

28. Costopoulos C, Latib A, Maisano F et al (2014) Comparison of results of transcatheter aortic valve implantation in patients with severely stenotic bicuspid versus tricuspid or nonbicuspid valves. Am J Cardiol 113:1390–1393

29. Kochman J, Huček Z, Scislo P et al (2014) Comparison of one- and 12-month outcomes of transcatheter aortic valve replacement in patients with severely stenotic bicuspid versus tricuspid aortic valves (results from a multicenter registry). Am J Cardiol 114:757–762

30. Seeger J, Gonska B, Rodewald C et al (2016) Bicuspid aortic stenosis treated with the repositionable and retrievable Lotus Valve. Can J Cardiol 32:135.e17–135.e19

31. Chan AW, Wong D, Charania J (2017) Transcatheter aortic valve replacement in bicuspid aortic stenosis using lotus valve system. Catheter Cardiovasc Interv 90(1):157–163

32. Tamburino C, Capodanno D, Ramondo A et al (2011) Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 123:299–308

33. Lefèvre T, Kappetein AP, Wolner E et al (2011) One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. Eur Heart J 32:148–157

34. Thomas M, Schymik G, Walther T et al (2011) One year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 124:425–433

35. Gilard M, Ethier N, Lung B et al (2012) Registry of transcatheter aortic-valve implantation in high risk patients. N Engl J Med 366:1705–1715

36. Webb JG, Wood DA (2012) Current status of transcatheter aortic valve replacement. J Am Coll Cardiol 60:483–492

37. Adams DJ, Pompia JJ, Reardon MJ et al (2014) Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370:1790–1798

38. Pompia JJ, Adams DH, Reardon MJ et al (2014) Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 63:1972–1981

39. Linke A, Wenaweser P, Gerckens U et al (2014) Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. Eur Heart J 35:2672–2684

40. Meredith IT, Worthley SG, Whitbourn RJ et al (2014) Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study. Eur J Cardiothorac Surg 47(6):1264–1270

41. Am MIT, Walters DL, Dumonteil N et al (2014) Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol 64(13):1339–1348

42. Falk V, Wohrle J, Hildick-Smith D et al (2017) Safety and efficacy of a fully repositionable and retrievable aortic valve used in routine clinical practice: the RESPOND Study. Eur Heart J 38(45):3359–3366

43. Montone RA, Testa L, Fraccaro C et al (2017) Procedural and 30-day clinical outcomes following transcatheter aortic valve replacement with lotus valve: results of the RELEVANT study. Catheter Cardiovasc Interv 90(7):1206–1211